logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

Regeneron Product REGN-EB3 Saving Lives Regeneron ( REGN )   announced that an independent monitoring board ended its investigational product REGN-EB3  trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals...

Read More

August 13, 2019

0

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

Gilead Sciences News Results from Phase 2/3 CAPELLA trial evaluating Gilead Sciences ( GILD )  lenacapavir achieved the primary endpoint in heavily treatment-experienced people with multidrug-resistant HIV-1 infection. The study showed that 88% of participants receiving lenacapavir experienced at least...

Read More

November 19, 2020

0

Regenxbio: Positive One-Year Data from the Firm's Gene Therapy RGX-314 for Wet AMD

Regenxbio Positive Data for RGX-314 Regenxbio ( RGNX ) reported positive one-year data from patients in Cohorts 4 and 5 from Phase I/IIa trial of RGX-314 for wet age-related macular degeneration ( wet AMD ). Regenxbio plans to initiate a...

Read More

August 4, 2020

0

The US FDA Approved Alnylam's OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

Alnylam Announces FDA Approval o f OXLUMO™ Injection for PH1 Alnylam ( ALNY ) announced that the US FDA has approved its subcutaneous OXLUMO™ (lumasiran) injection, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 ( PH1...

Read More

November 24, 2020

0

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

Gilead Sciences Was Issued a CLR from the FDA for Filgotinib Gilead Sciences ( GILD ) is in receipt of a complete response letter ( CRL ) from the U.S. Food and Drug Administration ( FDA ) for the New...

Read More

August 19, 2020

0

The Medicines Company Has Agreeable News

The Medicines Company The Medicines Company ( MDCO ) focuses on cardiovascular diseases. Major goals are halting the progression of atherosclerosis and lowering the cardiovascular risk caused by high levels of LDL Cholesterol ( LDL-C ). The firm announced good...

Read More

August 27, 2019

0

Gene Therapy and Other Treatments That Work at the Genetic Level

Gene Therapy Stocks Experiencing Selloffs  Every investor in the biotech sector must have experienced selloffs of the stocks from companies specialized in gene therapy, gene editing, antisense, RNAi and mRNA therapies. Recently, bluebird bio’s ( BLUE ) stock was devastated....

Read More

August 30, 2019

0

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis ( EXEL ) announced the submission of a supplemental New Drug Application ( sNDA ) to the U.S. FDA for CABOMETYX® ( cabozantinib ) in combination with Opdivo® (nivolumab)...

Read More

August 25, 2020

0

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

Reata Pharmaceuticals: Why its Stock Price is Down Reata Pharmaceuticals ( RETA ) announced that it has priced a public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share...

Read More

December 2, 2020

0

Vertex: In Pursuit of Cures

Vertex Pharmaceuticals Is Acquiring Semma Therapeutics Vertex Pharmaceutical ( VRTX ) entered into a definitive agreement to buy a private company, Semma Therapeutics. Semma  uses stem cell-derived human islets as a potential cure for type 1 diabetes. Semma’s major scientific advances...

Read More

September 4, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 101
  • 102
  • 103
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy